WASHINGTON, March 24 (Reuters) - Omrix Biopharmaceuticals Inc., which develops biosurgical and passive immunotherapy products, on Friday said it is planning to sell about 3.4 million shares for between $15 and $17 per share.
WASHINGTON, March 24 (Reuters) - Omrix Biopharmaceuticals Inc., which develops biosurgical and passive immunotherapy products, on Friday said it is planning to sell about 3.4 million shares for between $15 and $17 per share.
